@article{ART001514392},
author={서정임},
title={To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine},
journal={Journal of the Korea Bioethics Association},
issn={1598-0324},
year={2010},
volume={11},
number={2},
pages={59-75}
TY - JOUR
AU - 서정임
TI - To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine
JO - Journal of the Korea Bioethics Association
PY - 2010
VL - 11
IS - 2
PB - The Korean Bioethics Association
SP - 59
EP - 75
SN - 1598-0324
AB - The topics in bioethics have been expanded widely and deeply by the development of science technology. In 21C, bioethics meets new subject, nanomedicine, which is the emerging technology converged with nanotechnology and medicine. As a result of competitive investments of many countries, some of the outcomes are coming to the stage of clinical trials or even to the market, beyond the R&D. However it has been rarely discussed about ethical, legal, and societal implications(ELSI) brought about from the development of nanomedicine, unlike making efforts to the technical development.
The purposes of this paper are to verify whether we can deal with the ELSI of nanomedicine with a view of bioethics and to suggest how we can regulate such issues by our policy. As a methode, I conducted literature analysis and extracted 14 ethical issues and 23 social issues in nanomedicine. The conclusions of this paper are such as following. Although we can investigate ELSI in nanomedicine with the aspect of bioethics due to the similarity of issues, we also should consider concept changes and safety problems that will be given rise to by the particularity of 'nano' materials and their functions. And we should begin to discuss about preparing proper regulations depending on the life cycle of nanomedicine product, from R&D and clinical trials to the market.
KW - Nanotechnology;Nanomedicine;Bioethics;ELSI
DO -
UR -
ER -
서정임. (2010). To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine. Journal of the Korea Bioethics Association, 11(2), 59-75.
서정임. 2010, "To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine", Journal of the Korea Bioethics Association, vol.11, no.2 pp.59-75.
서정임 "To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine" Journal of the Korea Bioethics Association 11.2 pp.59-75 (2010) : 59.
서정임. To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine. 2010; 11(2), 59-75.
서정임. "To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine" Journal of the Korea Bioethics Association 11, no.2 (2010) : 59-75.
서정임. To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine. Journal of the Korea Bioethics Association, 11(2), 59-75.
서정임. To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine. Journal of the Korea Bioethics Association. 2010; 11(2) 59-75.
서정임. To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine. 2010; 11(2), 59-75.
서정임. "To Offer a Basis for Expansion of Bioethics Research Area and Public Policy Making : Ethical issues Analysis and Regulation Policy Recommendation in Nanomedicine" Journal of the Korea Bioethics Association 11, no.2 (2010) : 59-75.